Dr Miller on Updates With ADCs and Emerging Targets in Ovarian Cancer

Eirwen M. Miller, MD, gynecologic oncologist, Allegheny Health Network West Penn Hospital, discusses updates on antibody-drug conjugates (ADCs) and emerging targets in ovarian cancer, as presented by Sarah Crafton, MD, of Allegheny Health Network, during an OncLive® State of the Science Summit™ (SOSS) on gynecologic cancers.

At the SOSS, Dr Crafton provided an insightful discussion on ADCs and emerging targets in ovarian cancer, Miller begins. The phase 3 MIRASOL trial (NCT04209855) yielded promising initial results with mirvetuximab soravtansine-gynx (Elahere) in patients with platinum-resistant ovarian cancer, she explains. Findings from MIRASOL were presented at the 2023 ASCO Annual Meeting, she explains. Notably, in December 2023, following the ASCO Meeting, the FDA granted priority review to mirvetuximab soravtansine in patients with folate receptor α (FRα)–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Mirvetuximab soravtansine led to an overall survival (OS) benefit in the MIRASOL population compared with investigator’s choice of chemotherapy, Miller explains. This treatment option is significant for patients with unmet needs, and has a favorable toxicity profile, she adds.

Given that many patients with platinum-resistant ovarian cancer have undergone extensive prior treatments with notable hematologic toxicities, the hematologic toxicities associated with mirvetuximab soravtansine are relatively well tolerated, Miller expands. Furthermore, the medical community’s growing experience with the medication has increased comfort levels regarding the management of ocular toxicities, she emphasizes. Oncologists are developing robust algorithms for ophthalmology referrals, fostering strong relationships with eye care professionals for regular eye exams, and proactively educating patients about ocular toxicity symptoms, she explains.

Mirvetuximab soravtansine stands out as an exciting medication, considering the challenge of eliciting favorable OS results in patients with platinum-resistant ovarian cancer, Miller continues. The impact of this agent on the treatment paradigm is already evident and will continue to reshape current practices, she notes.

Dr Crafton also highlighted ADCs under investigation in clinical trials for patients with ovarian cancer, many of which target FRα and some of which are directed toward TROP-2, Miller adds. Miller concludes by stating that several trials are open for enrollment or will soon be available, emphasizing the importance of enrolling patients to these trials to propel advancements in this field.